Kristin Martin - Poseida Therapeutics Chief Officer
| PSTX Stock | USD 9.31 0.02 0.21% |
Insider
Kristin Martin is Chief Officer of Poseida Therapeutics
| Address | 9390 Towne Centre Drive, San Diego, CA, United States, 92121 |
| Phone | 858 779 3100 |
| Web | https://poseida.com |
Poseida Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.1311) % which means that it has lost $0.1311 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5763) %, meaning that it created substantial loss on money invested by shareholders. Poseida Therapeutics' management efficiency ratios could be used to measure how well Poseida Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.48 in 2024. Return On Capital Employed is likely to drop to -0.67 in 2024. At this time, Poseida Therapeutics' Net Tangible Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 1.8 M in 2024, whereas Other Assets are likely to drop slightly above 1.2 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Cameron MD | Generation Bio Co | 54 | |
| Joanna Siegall | Cytokinetics | N/A | |
| Alexander Zurcher | Molecular Partners AG | 49 | |
| Path FRCP | Revolution Medicines | 61 | |
| Kyle Breidenstine | PepGen | N/A | |
| CPA CPA | Stoke Therapeutics | 63 | |
| Josh Eizen | AN2 Therapeutics | N/A | |
| FACC MD | Stoke Therapeutics | 61 | |
| MBA BS | AN2 Therapeutics | 49 | |
| Michael Pitzner | Molecular Partners AG | N/A | |
| JD MSc | Cue Biopharma | 61 | |
| Johannes Hull | Pliant Therapeutics | 49 | |
| Annick Deschoolmeester | Pharvaris BV | 51 | |
| Maryann Cimino | Pharvaris BV | N/A | |
| Kishor Bhatia | Lantern Pharma | 69 | |
| Mark Wallet | Century Therapeutics | N/A | |
| DVM MS | Lantern Pharma | N/A | |
| Patrick Amstutz | Molecular Partners AG | 49 | |
| Lawrence Lamb | In8bio Inc | 69 | |
| Noel MBA | PepGen | 54 | |
| Andreas EMBA | Molecular Partners AG | 58 | |
Management Performance
| Return On Equity | -0.58 | ||||
| Return On Asset | -0.13 |
Poseida Therapeutics Leadership Team
Elected by the shareholders, the Poseida Therapeutics' board of directors comprises two types of representatives: Poseida Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Poseida. The board's role is to monitor Poseida Therapeutics' management team and ensure that shareholders' interests are well served. Poseida Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Poseida Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Loren Wagner, Senior Operations | ||
| Sarah Thailing, Senior IR | ||
| JD Esq, Chief Counsel | ||
| Johanna CPA, Chief Officer | ||
| Kristin Martin, Chief Officer | ||
| Alexander Chapman, Senior Communications | ||
| Karen MBA, Senior Development | ||
| Brent Warner, President Therapy | ||
| Mark JD, Executive Board | ||
| Devon Shedlock, Chief Therapy | ||
| Lisa Portale, Senior Affairs | ||
| Kristin Yarema, CEO President | ||
| Dr JD, Senior Counsel |
Poseida Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Poseida Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.58 | ||||
| Return On Asset | -0.13 | ||||
| Profit Margin | (0.40) % | ||||
| Operating Margin | 0.28 % | ||||
| Current Valuation | 759.29 M | ||||
| Shares Outstanding | 97.47 M | ||||
| Shares Owned By Insiders | 27.64 % | ||||
| Shares Owned By Institutions | 58.48 % | ||||
| Number Of Shares Shorted | 4.61 M | ||||
| Price To Earning | 214.00 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Poseida Stock Analysis
When running Poseida Therapeutics' price analysis, check to measure Poseida Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Poseida Therapeutics is operating at the current time. Most of Poseida Therapeutics' value examination focuses on studying past and present price action to predict the probability of Poseida Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Poseida Therapeutics' price. Additionally, you may evaluate how the addition of Poseida Therapeutics to your portfolios can decrease your overall portfolio volatility.